These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 9322677)

  • 21. Systematic review of the presentation of coagulation factor VIII inhibitors in rheumatic diseases: A potential cause of life-threatening hemorrhage.
    O'Connor CR
    Semin Arthritis Rheum; 2015 Jun; 44(6):695-709. PubMed ID: 25595725
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune tolerance therapy in patients with acquired hemophilia.
    von Depka M
    Hematology; 2004 Aug; 9(4):245-57. PubMed ID: 15621732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor VIII inhibitors.
    Lollar P; Healey JF; Barrow RT; Parker ET
    Adv Exp Med Biol; 2001; 489():65-73. PubMed ID: 11554592
    [No Abstract]   [Full Text] [Related]  

  • 24. [The antiphospholipid antibody syndrome: its pathogenesis and clinico-morphological manifestations].
    Zerbino DD; Lukasevich LL; Bilynskaia OA
    Arkh Patol; 1990; 52(4):65-9. PubMed ID: 2117434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome.
    Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A
    Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb).
    Jansen M; Schmaldienst S; Banyai S; Quehenberger P; Pabinger I; Derfler K; Hörl WH; Knöbl P
    Br J Haematol; 2001 Jan; 112(1):91-7. PubMed ID: 11167789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 28. Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy.
    Cugno M; Gualtierotti R; Tedeschi A; Meroni PL
    Autoimmun Rev; 2014 Jan; 13(1):40-8. PubMed ID: 23954454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.
    Miller CH; Rice AS; Boylan B; Shapiro AD; Lentz SR; Wicklund BM; Kelly FM; Soucie JM;
    J Thromb Haemost; 2013 Jul; 11(7):1300-9. PubMed ID: 23601690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Auto- and alloantibodies against factor XIII: laboratory diagnosis and clinical consequences.
    Muszbek L; Pénzes K; Katona É
    J Thromb Haemost; 2018 May; 16(5):822-832. PubMed ID: 29460500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiphospholipid-protein antibodies: clinical use of laboratory test results (identification, predictive value, treatment).
    Triplett DA
    Haemostasis; 1996 Oct; 26 Suppl 4():358-67. PubMed ID: 8979140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitors in congenital coagulation disorders.
    Key NS
    Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiphospholipid antibodies in children without and in adults with and without thrombophilia.
    Siemens HJ; Gutsche S; Brückner S; Bucsky P; Katus HA
    Thromb Res; 2000 May; 98(4):241-7. PubMed ID: 10822070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of rare anti-phospholipid/protein co-factor autoantibodies in patients with systemic lupus erythematosus.
    Szodoray P; Tarr T; Tumpek J; Kappelmayer J; Lakos G; Poor G; Szegedi G; Kiss E
    Autoimmunity; 2009 Sep; 42(6):497-506. PubMed ID: 19626489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autoantibody explosion in antiphospholipid syndrome.
    Shoenfeld Y; Twig G; Katz U; Sherer Y
    J Autoimmun; 2008; 30(1-2):74-83. PubMed ID: 18171610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening of F.VIII:C antibodies by an enzyme-linked immunosorbent assay.
    Mondorf W; Ehrenforth S; Vigh Z; Last J; Tippmann G; Kreuz W; Scharrer I
    Vox Sang; 1994; 66(1):8-13. PubMed ID: 8146988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 38. Recent improvements in the clinical treatment of coagulation factor inhibitors.
    Franchini M; Lippi G
    Semin Thromb Hemost; 2009 Nov; 35(8):806-13. PubMed ID: 20169517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired inhibitors of blood coagulation.
    Feinstein DI; Rapaport SI
    Prog Hemost Thromb; 1972; 1():75-95. PubMed ID: 4569725
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antiphospholipid antibodies: clinical significance and biological diagnosis].
    Arnoux D; Boutière B; Sanmarco M
    Ann Biol Clin (Paris); 2000; 58(5):557-74. PubMed ID: 11022099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.